| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24.3 | 33.3 |
| Gross profit | 13.7 | 22.0 |
| Profit before tax | -3.4 | 1.6 |
| Net income | -3.6 | 1.3 |
| EPS (diluted, $ a share) | $-0.03 | $0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -27.0% |
|---|---|
| Gross margin | 56.3% |
| Operating margin | -12.5% |
10-Q filed with the SEC, NYSE: XTNT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Xtant Medical Holdings, Inc.: key numbers
- Share price
- $0.2098Close, Nov 16
- Market cap
- $29.5M
- Shares outstanding
- 140.45MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Xtant Medical Holdings, Inc.
All →Xtant Medical Holdings Financial Results
Xtant Medical reported Q3 2026 revenue of $24.3 million, a decrease from $33.3 million in the prior year primarily due to divested businesses and the absence of wound care licensing revenue. The company's Board of Directors also announced a formal strategic review process to evaluate operational improvements, capital structure alternatives, and potential business combinations or transactions.
- Term
- Q3 2026
“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable.”
Stavros Vizirgianakis, Chairman of the Board
“The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process.”
Stavros Vizirgianakis, Chairman of the Board